Novartis has agreed to pay up to $3 billion to license Alteogen's Hybrozyme platform, which uses an enzyme to allow large biologic drugs to be absorbed faster via subcutaneous injections instead of long intravenous infusions. This innovation could improve patient convenience and help Novartis defend its existing drug franchises against competition from generics and biosimilars. The deal's milestone and royalty payments reflect the lower risk of reformulating existing drugs rather than developing new ones. Novartis aims to leverage this technology to maintain market share and enhance drug administration efficiency, although adoption may face challenges from established medical practices and infusion center economics.
